Market Research Logo

Bladder Cancer - Pipeline Review, H2 2015

Introduction
Global Markets Direct Report Coverage
Bladder Cancer Overview
Therapeutics Development
Pipeline Products for Bladder Cancer - Overview
Pipeline Products for Bladder Cancer - Comparative Analysis
Bladder Cancer - Therapeutics under Development by Companies
Bladder Cancer - Therapeutics under Investigation by Universities/Institutes
Bladder Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Bladder Cancer - Products under Development by Companies
Bladder Cancer - Products under Investigation by Universities/Institutes
Bladder Cancer - Companies Involved in Therapeutics Development
Advaxis, Inc.
Alligator Bioscience AB
Alnylam Pharmaceuticals, Inc.
Altor BioScience Corporation
AndroScience Corporation
APIM Therapeutics AS
Arno Therapeutics, Inc.
Ascenta Therapeutics, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
AuraSense Therapeutics, LLC
AVEO Pharmaceuticals, Inc.
AvidBiotics Corp.
Bavarian Nordic A/S
Bayer AG
BioCancell Ltd
Bioncotech Therapeutics S.L.
Biotest AG
cCAM Biotherapeutics Ltd.
Celgene Corporation
Celldex Therapeutics, Inc.
Cold Genesys, Inc.
Daiichi Sankyo Company, Limited
DormaTarg, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
EntreChem, S.L.
Esperance Pharmaceuticals, Inc.
Evotec AG
F. Hoffmann-La Roche Ltd.
Gene Signal International SA
Genmab A/S
GlaxoSmithKline Plc
Heat Biologics, Inc.
Horizon Pharma Plc
Hutchison MediPharma Limited
Idera Pharmaceuticals, Inc.
Immunomedics, Inc.
Immupharma Plc
ImmuRx, Inc.
Ludwig Institute For Cancer Research Ltd
MacroGenics, Inc.
Marina Biotech, Inc.
Meabco A/S
MedImmune, LLC
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
NuCana BioMed Limited
Omeros Corporation
Oncogenex Pharmaceuticals, Inc.
Oncolytics Biotech Inc.
Oncopeptides AB
Ono Pharmaceutical Co., Ltd.
Optimum Therapeutics, LLC
Panacela Labs, Inc.
Pfizer Inc.
Pharma Mar, S.A.
Polaris Pharmaceuticals, Inc.
PsiOxus Therapeutics Limited
Qu Biologics Inc.
Quest PharmaTech Inc.
Samyang Holdings Corporation
Sanofi
Serometrix, LLC
Shionogi & Co., Ltd.
Sorrento Therapeutics, Inc.
Spectrum Pharmaceuticals, Inc.
Stemline Therapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Sun Pharma Advanced Research Company Ltd.
Synta Pharmaceuticals Corp.
TARIS BioMedical, Inc.
Telesta Therapeutics Inc.
Telormedix SA
Theravectys SA
TheRyte Limited
Tolero Pharmaceuticals, Inc.
Transgene SA
Vakzine Projekt Management GmbH
Vaxeal Holding SA
Viralytics Ltd.
Viventia Biotechnologies Inc.
Bladder Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACP-196 - Drug Profile
ADC-1013 - Drug Profile
afuresertib hydrochloride + trametinib dimethyl sulfoxide - Drug Profile
aganirsen - Drug Profile
ALT-801 - Drug Profile
ALT-803 - Drug Profile
amrubicin hydrochloride - Drug Profile
Antibody to Inhibit TYRO-3 for Bladder Cancer - Drug Profile
Antisense Oligonucleotides for Bladder Cancer - Drug Profile
Antisense RNAi Oligonucleotides to Inhibit Survivin for Pancreatic Cancer - Drug Profile
apatorsen - Drug Profile
apaziquone - Drug Profile
APL-1202 - Drug Profile
APTA-012 - Drug Profile
AR-42 - Drug Profile
ASC-JM.Z1 - Drug Profile
ASG-15ME - Drug Profile
AST-008 - Drug Profile
AT-406 - Drug Profile
atezolizumab - Drug Profile
ATX-101 - Drug Profile
AV-203 - Drug Profile
AZD-4547 - Drug Profile
AZD-5312 - Drug Profile
B-701 - Drug Profile
BAY-1163877 - Drug Profile
BC-819 - Drug Profile
Biologic for Superficial Bladder Cancer - Drug Profile
BO-110 - Drug Profile
BPC-1 - Drug Profile
BV-2711 - Drug Profile
CDX-1401 - Drug Profile
Cell Therapy for Bladder Cancer - Drug Profile
Cell Therapy to Target HER2 for Oncology - Drug Profile
CG-0070 - Drug Profile
CM-24 - Drug Profile
CV-301 - Drug Profile
CVA-21 - Drug Profile
DAB-389EGF - Drug Profile
Dendritic Cell Therapy to Target HER-2 for Oncology - Drug Profile
docetaxel - Drug Profile
Drug for NMIBC - Drug Profile
Drugs to Inhibit FGFR3 for Bladder Cancer - Drug Profile
Drugs to Inhibit TYRO-3 for Bladder Cancer - Drug Profile
dsP21-322-2'F - Drug Profile
DT-310 - Drug Profile
DT-320 - Drug Profile
DT-330 - Drug Profile
durvalumab + tremelimumab - Drug Profile
EC-7072 - Drug Profile
enadenotucirev - Drug Profile
enoblituzumab - Drug Profile
EP-400 - Drug Profile
eribulin mesylate - Drug Profile
erlotinib hydrochloride - Drug Profile
GSK-2849330 - Drug Profile
HMPL-453 - Drug Profile
HuMax-TF-ADC - Drug Profile
ICT-2700 - Drug Profile
imiquimod - Drug Profile
IMO-2055 - Drug Profile
indatuximab ravtansine - Drug Profile
interferon gamma-1b - Drug Profile
IPP-204106 - Drug Profile
JAAF-11 - Drug Profile
lenalidomide - Drug Profile
Lm-LLO-ISG15 - Drug Profile
lurbinectedin - Drug Profile
MDNA-55 - Drug Profile
MDR-09521 - Drug Profile
Melflufen - Drug Profile
mitomycin SR - Drug Profile
MMD-37K - Drug Profile
mocetinostat - Drug Profile
Monoclonal Antibodies to Inhibit VISTA for Bladder Cancer - Drug Profile
Monoclonal Antibody to Inhibit EGFR for Superficial Bladder Cancer - Drug Profile
MVAME-03 - Drug Profile
MVXONCO-1 - Drug Profile
nivolumab - Drug Profile
NUC-1031 - Drug Profile
OGX-225 - Drug Profile
oportuzumab monatox - Drug Profile
paclitaxel - Drug Profile
paclitaxel albumin bound - Drug Profile
paclitaxel albumin free - Drug Profile
patritumab - Drug Profile
pegargiminase - Drug Profile
pelareorep - Drug Profile
pembrolizumab - Drug Profile
QBECP-SSI - Drug Profile
rAd-IFN - Drug Profile
ramucirumab - Drug Profile
recMAGE-A3 + AS15 - Drug Profile
Recombinant BCG - Pertussis Vaccine - Drug Profile
Recombinant Protein for Oncology and Infectious Disease - Drug Profile
RNAi Oligonucleotide to Inhibit TYRO-3 for Bladder Cancer - Drug Profile
S-588410 - Drug Profile
sacituzumab govitecan - Drug Profile
sapanisertib - Drug Profile
SAR-408701 - Drug Profile
SGT-94 - Drug Profile
sirolimus albumin-bound - Drug Profile
SL-052 - Drug Profile
SL-601 - Drug Profile
Small molecule for Bladder Cancer - Drug Profile
Small Molecule to Antagonize GPR87 for Cancer - Drug Profile
Small Molecule to Inhibit TDO-2 for Cancer - Drug Profile
Small Molecule to Inhibit TYRO3 for Bladder Cancer - Drug Profile
Small Molecules to Activate Caspase 3 and Caspase 9 for Bladder and Urinary Tract Cancer - Drug Profile
Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile
STA-128666 - Drug Profile
sunitinib malate - Drug Profile
suramin hexasodium - Drug Profile
SVX-1 - Drug Profile
SX-MTR1 - Drug Profile
TD-210 - Drug Profile
temsirolimus - Drug Profile
TF-011 Monomethyl Auristatin E - Drug Profile
TG-6002 - Drug Profile
THR-53 - Drug Profile
TMX-202 - Drug Profile
TP-3654 - Drug Profile
TT-16 - Drug Profile
Urocidin - Drug Profile
Vaccine for Bladder Cancer - Drug Profile
Vaccine to Target NY-ESO-1 for Oncology - Drug Profile
vemurafenib - Drug Profile
vesigenurtucel-L - Drug Profile
VPM-1002 - Drug Profile
Bladder Cancer - Recent Pipeline Updates
Bladder Cancer - Dormant Projects
Bladder Cancer - Discontinued Products
Bladder Cancer - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Bladder Cancer, H2 2015
Number of Products under Development for Bladder Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Investigation by Universities/Institutes, H2 2015
Bladder Cancer - Pipeline by Advaxis, Inc., H2 2015
Bladder Cancer - Pipeline by Alligator Bioscience AB, H2 2015
Bladder Cancer - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2015
Bladder Cancer - Pipeline by Altor BioScience Corporation, H2 2015
Bladder Cancer - Pipeline by AndroScience Corporation, H2 2015
Bladder Cancer - Pipeline by APIM Therapeutics AS, H2 2015
Bladder Cancer - Pipeline by Arno Therapeutics, Inc., H2 2015
Bladder Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2015
Bladder Cancer - Pipeline by Astellas Pharma Inc., H2 2015
Bladder Cancer - Pipeline by AstraZeneca Plc, H2 2015
Bladder Cancer - Pipeline by AuraSense Therapeutics, LLC, H2 2015
Bladder Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
Bladder Cancer - Pipeline by AvidBiotics Corp., H2 2015
Bladder Cancer - Pipeline by Bavarian Nordic A/S, H2 2015
Bladder Cancer - Pipeline by Bayer AG, H2 2015
Bladder Cancer - Pipeline by BioCancell Ltd, H2 2015
Bladder Cancer - Pipeline by Bioncotech Therapeutics S.L., H2 2015
Bladder Cancer - Pipeline by Biotest AG, H2 2015
Bladder Cancer - Pipeline by cCAM Biotherapeutics Ltd., H2 2015
Bladder Cancer - Pipeline by Celgene Corporation, H2 2015
Bladder Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2015
Bladder Cancer - Pipeline by Cold Genesys, Inc., H2 2015
Bladder Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Bladder Cancer - Pipeline by DormaTarg, Inc., H2 2015
Bladder Cancer - Pipeline by Eisai Co., Ltd., H2 2015
Bladder Cancer - Pipeline by Eli Lilly and Company, H2 2015
Bladder Cancer - Pipeline by EntreChem, S.L., H2 2015
Bladder Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2015
Bladder Cancer - Pipeline by Evotec AG, H2 2015
Bladder Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Bladder Cancer - Pipeline by Gene Signal International SA, H2 2015
Bladder Cancer - Pipeline by Genmab A/S, H2 2015
Bladder Cancer - Pipeline by GlaxoSmithKline Plc, H2 2015
Bladder Cancer - Pipeline by Heat Biologics, Inc., H2 2015
Bladder Cancer - Pipeline by Horizon Pharma Plc, H2 2015
Bladder Cancer - Pipeline by Hutchison MediPharma Limited, H2 2015
Bladder Cancer - Pipeline by Idera Pharmaceuticals, Inc., H2 2015
Bladder Cancer - Pipeline by Immunomedics, Inc., H2 2015
Bladder Cancer - Pipeline by Immupharma Plc, H2 2015
Bladder Cancer - Pipeline by ImmuRx, Inc., H2 2015
Bladder Cancer - Pipeline by Ludwig Institute For Cancer Research Ltd, H2 2015
Bladder Cancer - Pipeline by MacroGenics, Inc., H2 2015
Bladder Cancer - Pipeline by Marina Biotech, Inc., H2 2015
Bladder Cancer - Pipeline by Meabco A/S, H2 2015
Bladder Cancer - Pipeline by MedImmune, LLC, H2 2015
Bladder Cancer - Pipeline by Merck & Co., Inc., H2 2015
Bladder Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Bladder Cancer - Pipeline by Mirati Therapeutics Inc., H2 2015
Bladder Cancer - Pipeline by NuCana BioMed Limited, H2 2015
Bladder Cancer - Pipeline by Omeros Corporation, H2 2015
Bladder Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2015
Bladder Cancer - Pipeline by Oncolytics Biotech Inc., H2 2015
Bladder Cancer - Pipeline by Oncopeptides AB, H2 2015
Bladder Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Bladder Cancer - Pipeline by Optimum Therapeutics, LLC, H2 2015
Bladder Cancer - Pipeline by Panacela Labs, Inc., H2 2015
Bladder Cancer - Pipeline by Pfizer Inc., H2 2015
Bladder Cancer - Pipeline by Pharma Mar, S.A., H2 2015
Bladder Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015
Bladder Cancer - Pipeline by PsiOxus Therapeutics Limited, H2 2015
Bladder Cancer - Pipeline by Qu Biologics Inc., H2 2015
Bladder Cancer - Pipeline by Quest PharmaTech Inc., H2 2015
Bladder Cancer - Pipeline by Samyang Holdings Corporation, H2 2015
Bladder Cancer - Pipeline by Sanofi, H2 2015
Bladder Cancer - Pipeline by Serometrix, LLC, H2 2015
Bladder Cancer - Pipeline by Shionogi & Co., Ltd., H2 2015
Bladder Cancer - Pipeline by Sorrento Therapeutics, Inc., H2 2015
Bladder Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015
Bladder Cancer - Pipeline by Stemline Therapeutics, Inc., H2 2015
Bladder Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
Bladder Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015
Bladder Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2015
Bladder Cancer - Pipeline by TARIS BioMedical, Inc., H2 2015
Bladder Cancer - Pipeline by Telesta Therapeutics Inc., H2 2015
Bladder Cancer - Pipeline by Telormedix SA, H2 2015
Bladder Cancer - Pipeline by Theravectys SA, H2 2015
Bladder Cancer - Pipeline by TheRyte Limited, H2 2015
Bladder Cancer - Pipeline by Tolero Pharmaceuticals, Inc., H2 2015
Bladder Cancer - Pipeline by Transgene SA, H2 2015
Bladder Cancer - Pipeline by Vakzine Projekt Management GmbH, H2 2015
Bladder Cancer - Pipeline by Vaxeal Holding SA, H2 2015
Bladder Cancer - Pipeline by Viralytics Ltd., H2 2015
Bladder Cancer - Pipeline by Viventia Biotechnologies Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Bladder Cancer Therapeutics - Recent Pipeline Updates, H2 2015
Bladder Cancer - Dormant Projects, H2 2015
Bladder Cancer - Dormant Projects (Contd..1), H2 2015
Bladder Cancer - Dormant Projects (Contd..2), H2 2015
Bladder Cancer - Dormant Projects (Contd..3), H2 2015
Bladder Cancer - Dormant Projects (Contd..4), H2 2015
Bladder Cancer - Dormant Projects (Contd..5), H2 2015
Bladder Cancer - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Bladder Cancer, H2 2015
Number of Products under Development for Bladder Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Bladder Cancer - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Bladder Cancer - Pipeline Review, H2 2015’, provides an overview of the Bladder Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bladder Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bladder Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Bladder Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Bladder Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Bladder Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Bladder Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;